Thiopurine S-methyltransferase pharmacogenetics: variant allele functional and comparative genomics
Authors:
- Liewei WangLWLiewei Wang
- Mathieu WiepertMWMathieu Wiepert
- Vivien C. YeeVYVivien C. Yee
- Richard M. WeinshilboumRWRichard M. Weinshilboum
- 1 November 2005
- journal article
- research article
- Published by Wolters Kluwer Health in Pharmacogenetics and Genomics
- Vol. 15 (11) , 801-815
Abstract
Thiopurine S-methyltransferase (TPMT) catalyses the S-methylation of thiopurine drugs. Genetic polymorphisms for TPMT are a major factor responsible for large individual variations in thiopurine toxicity and therapeutic effect. The present study investigated the functional effects of human TPMT variant alleles that alter the encoded amino acid sequence of the enzyme, TPMT*2, *3A, *3B, *3C and *5 to *13. After expression in COS-1 cells and correction for transfection efficiency, allozymes encoded by these alleles displayed levels of activity that varied from virtually undetectable (*3A,*3B and *5) to 98% (*7) of that observed for the wild-type allele. Although some allozymes had significant elevations in apparent K m values for 6-mercaptopurine and S-adenosyl-L-methionine (i.e. the two cosubstrates for the reaction), the level of enzyme protein was the major factor responsible for variation in activity. Quantitative Western blot analysis demonstrated that the level of enzyme protein correlated closely with level of activity for all allozymes except TPMT*5. Furthermore, protein levels correlated with rates of TPMT degradation. TPMT amino acid sequences were then determined for 16 non-human mammalian species and those sequences (plus seven reported previously, including two nonmammalian vertebrate species) were used to determine amino acid sequence conservation. Most human TPMT variant allozymes had alterations of residues that were highly conserved during vertebrate evolution. Finally, a human TPMT homology structural model was created on the basis of a Pseudomonas structure (the only TPMT structure solved to this time), and the model was used to infer the functional consequences of variant allozyme amino acid sequence alterations. These studies indicate that a common mechanism responsible for alterations in the activity of variant TPMT allozymes involves alteration in the level of enzyme protein due, at least in part, to accelerated degradation.Keywords
This publication has 56 references indexed in Scilit:
- Inheritance and Drug ResponseNew England Journal of Medicine, 2003
- Thiopurine methyltransferase polymorphic tandem repeat: Genotype-phenotype correlation analysisClinical Pharmacology & Therapeutics, 2000
- METHYLATION PHARMACOGENETICS: Catechol O-Methyltransferase, Thiopurine Methyltransferase, and Histamine N-MethyltransferaseAnnual Review of Pharmacology and Toxicology, 1999
- Thiopurine Methyltransferase Pharmacogenetics: Human Gene Cloning and Characterization of a Common PolymorphismDNA and Cell Biology, 1996
- The clinical pharmacology of 6-mercaptopurineEuropean Journal of Clinical Pharmacology, 1992
- Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemiaThe Journal of Pediatrics, 1991
- Thiopurine pharmacogenetics in leukemia: Correlation of erythrocyte thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrationsClinical Pharmacology & Therapeutics, 1987
- Childhood leukaemia: a relationship between intracellular 6‐ mercaptopurine metabolites and neutropenia.British Journal of Clinical Pharmacology, 1983
- Human kidney thiopurine methyltransferase purification and biochemical propertiesBiochemical Pharmacology, 1983
- Metabolism of Thiopyrimidines and ThiopurinesJournal of Biological Chemistry, 1963